Last reviewed · How we verify

Enalapril and carvedilol

Hospital Clinic of Barcelona · Phase 3 active Small molecule

Enalapril and carvedilol is a ACE inhibitor and beta-blocker combination Small molecule drug developed by Hospital Clinic of Barcelona. It is currently in Phase 3 development for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.

This combination reduces blood pressure and heart workload by blocking angiotensin II formation (enalapril) and beta-adrenergic signaling (carvedilol).

This combination reduces blood pressure and heart workload by blocking angiotensin II formation (enalapril) and beta-adrenergic signaling (carvedilol). Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.

At a glance

Generic nameEnalapril and carvedilol
SponsorHospital Clinic of Barcelona
Drug classACE inhibitor and beta-blocker combination
TargetACE (angiotensin-converting enzyme) and beta-adrenergic receptors
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Enalapril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Carvedilol is a non-selective beta-blocker with alpha-blocking properties that decreases heart rate, contractility, and peripheral vascular resistance. Together, they provide complementary cardiovascular protection in heart failure and hypertension.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Enalapril and carvedilol

What is Enalapril and carvedilol?

Enalapril and carvedilol is a ACE inhibitor and beta-blocker combination drug developed by Hospital Clinic of Barcelona, indicated for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.

How does Enalapril and carvedilol work?

This combination reduces blood pressure and heart workload by blocking angiotensin II formation (enalapril) and beta-adrenergic signaling (carvedilol).

What is Enalapril and carvedilol used for?

Enalapril and carvedilol is indicated for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction management.

Who makes Enalapril and carvedilol?

Enalapril and carvedilol is developed by Hospital Clinic of Barcelona (see full Hospital Clinic of Barcelona pipeline at /company/hospital-clinic-of-barcelona).

What drug class is Enalapril and carvedilol in?

Enalapril and carvedilol belongs to the ACE inhibitor and beta-blocker combination class. See all ACE inhibitor and beta-blocker combination drugs at /class/ace-inhibitor-and-beta-blocker-combination.

What development phase is Enalapril and carvedilol in?

Enalapril and carvedilol is in Phase 3.

What are the side effects of Enalapril and carvedilol?

Common side effects of Enalapril and carvedilol include Hypotension, Dizziness, Fatigue, Cough, Hyperkalemia, Bradycardia.

What does Enalapril and carvedilol target?

Enalapril and carvedilol targets ACE (angiotensin-converting enzyme) and beta-adrenergic receptors and is a ACE inhibitor and beta-blocker combination.

Related